BMI1 and acute myeloid leukemia: While the BCL2 inhibitor venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC), has been approved for the treatment of adults with newly diagnosed AML [5], the MCL1 inhibitor S63845 has been evaluated as a candidate treatment in AML in combination with the MEK inhibitor trametinib, the BMI1 inhibitor PTC596, or the HSP90 inhibitor PU-H71 in preclinical studies [6,7,8].